Biocon & Mylan to present final overall survival data of biosimilar for cancer

HERTFORDSHIRE (ENGLAND) | PITTSBURGH (US) | BENGALURU | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT  – In a press release submitted to the Exchanges in India on Thursday, Biocon Ltd said of Biocon and Mylan to Present Final Overall Survival Data for Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin4P, at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Ogivri™ is the first biosimilar for Herceptin” approved by the U.S. Food and Drug Administration (FDA) for all indications including HER2-positive breast and gastric cancers.

The filing read, Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that final data from the HERITAGE study will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

The HERITAGE study compared Ogivri™ to the reference product, Herceptin”, in patients with HER2+ metastatic breast cancer in combination with taxanes for the first 24 weeks and then as a monotherapy until progression.

Safety and overall survival, cumulative through 36 months of follow-up, will be presented as part of the Breast Cancer – Metastatic session, “HER2-Positive Disease: How Far Have We Come?,” on June 2.

For more details, please click the link, given here : https://buff.ly/30oEFow


Follow DATELINE GUJARAT On :-

FacebookGoogle+LinkedinTwitterYouTube 


SHARE THIS NEWS ON :-